Authors: Maudy Gayet Anouk van der Aa Peter Schmitz Harrie P Beerlage Bart Ph Schrier Peter F A Mulders Massimo Mischi Hessel Wijkstra
Publish Date: 2016/02/04
Volume: 34, Issue: 9, Pages: 1255-1260
Abstract
To overcome the limitations regarding transrectal ultrasound TRUSguided biopsies in prostate cancer PCa detection there is a focus on new imaging technologies The Navigo™ system UCcare Israel uses regular TRUS images and electrospatial monitoring to generate a 3D model of the prostate The aim of this study was to compare cancer detection rates between the Navigo™ system and conventional TRUS in patients without a history of PCaA total of 325 patients met our inclusion criteria 778 of biopsy sessions were performed using the Navigo™ system There was no statistically significant difference in PCa detection 399 vs 462 with Navigo™ system and TRUS respectively Using the Navigo™ system for taking prostate biopsies proved not to be associated with the presence of PCa at biopsy likewise for clinically significant PCa and for both subgroupsThe limitations of the study include its retrospective design the limited number of patients in the conventional TRUS group the statistically significant different number of biopsy sessions and the ones performed by an advanced physician in both groupsA van der Aa was involved in data collection and manuscript writing H Beerlage M Mischi P Mulders B Schrier and H Wijkstra was involved in protocol/project development M Gayet was involved in data collection and management data analysis and manuscript writing and P Schmitz was involved in data collection
Keywords: